Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-05221304 in NAFLD/NASH
NCT04395950Phase 1Withdrawn
- Sponsor
- Columbia University
- Start
- Dec 2020
- Primary completion
- Aug 2021
- Modality
- Small Molecules
01
Overview
Phase 1, single-blind, single-arm trial of clesacostat in Nonalcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD), sponsored by Columbia University. Primary endpoints: Rate of Secretion of VLDL TG at 20 weeks and Fractional Clearance Rate of VLDL TG at 20 weeks. Planned start Dec 2020; status: withdrawn.
02
Drugs
clesacostat
03
Conditions
Nonalcoholic steatohepatitis (NASH)non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT04395950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04395950.